Guilty Plea Expected in Killing of UnitedHealthcare CEO; State Trial Hangs in Balance
Luigi Mangione, the 28-year-old man accused of killing UnitedHealthcare CEO Brian Thompson in December 2024, is scheduled to appear in federal court on Friday for a hearing at which he is expected to plead guilty, according to a person familiar with the matter. The person, who spoke to The Associated Press on condition of anonymity, said Mangione could still change his mind about the plea. Earlier plea negotiations in June broke down, the person added.
Lawyers for Mangione and the Justice Department declined to comment ahead of the late-morning hearing, which was requested jointly by prosecutors and defence lawyers earlier this week. The federal and state cases against Mangione stem from the same incident: the ambush of Thompson outside a New York City hotel on December 4, 2024, as the insurance executive walked to UnitedHealth Group’s annual investor conference.
Mangione faces two federal charges of stalking Thompson with the intent to cause his death. Both the federal and state prosecutions could result in life imprisonment. A federal judge earlier this year dismissed additional charges that could have exposed Mangione to the death penalty. A state trial on murder charges is scheduled to begin next month, but it remains unclear whether that trial would proceed if Mangione pleads guilty in the federal case.
The issue of double jeopardy has been a central point of contention. Mangione had earlier told a judge: “It’s the same trial twice. One plus one is two. Double jeopardy by any commonsense definition.” Under New York law, a state prosecution may be barred if a federal case is resolved first, as double jeopardy protections kick in once a jury is sworn in or a guilty plea is entered. However, the charges in the two cases are not identical, which complicates the legal analysis. State prosecutors last month objected in writing to the possibility that a guilty plea in the federal case would wipe out the state case.
The case has also drawn considerable public attention. Mangione, a University of Pennsylvania graduate from a wealthy Maryland family, was arrested five days after the shooting at a McDonald’s in Altoona, Pennsylvania, about 230 miles west of Manhattan. Surveillance video showed a masked gunman shooting Thompson from behind. Police said the ammunition used bore the words “delay,” “deny” and “depose,” echoing a phrase often used to describe how insurers avoid paying claims.
In the federal case, U.S. District Judge Margaret M. Garnett has ruled that evidence from Mangione’s backpack, including a 3D-printed pistol and a notebook, could be used against him. Investigators said the pistol matched the weapon used in the killing, and the notebook allegedly described Mangione’s intent to kill an insurance executive. In June, Mangione’s lawyers briefly announced they would pursue a psychiatric defence in the state case, citing extreme emotional disturbance, but they reversed course a day later. Such a defence is not available in federal court.
For some people, Mangione has become a cause célèbre, reflecting public frustration with the health insurance industry. Legal experts, however, emphasise that the judicial process must focus on the facts and the law, ensuring a fair trial for the accused while acknowledging the seriousness of the crime and the loss suffered by Thompson’s family and colleagues.
Friday’s hearing is expected to clarify Mangione’s intentions. If he formally enters a guilty plea, it could have far-reaching implications for the separate state prosecution and the double jeopardy questions at the heart of the case. The proceedings will be watched closely by both legal observers and the public.
